Vitiligo Registry for Adults and Children in the UK

Trial statusNot yet recruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
AgeNot listed
SponsorThe Royal Wolverhampton Hospitals NHS Trust

About this trial

Vitiligo is the most common depigmentation disorder affecting around 1% of the population worldwide. Fifty two percent of patients develop vitiligo before the age of 20 and around 80% develop vitiligo before the age of 30 years old.1 Vitiligo often presents in childhood and tends to be a lifelong disease, requiring prolonged courses of phototherapy.

Currently no national or international registry for patients with vitiligo exists. Individual dermatologists maintain a database of such patients, however no coordinated efforts have been made to combine these individual registries into a broader national registry. Finally, recently published British Association of Dermatologists (BAD) guideline for the management of vitiligo, recommended the development of a national registry for people with vitiligo undergoing systemic or light therapy to identify outcomes and safety.

Eligibility criteria

Qualifiers

Paediatric and adult patients with vitiligo under management in secondary care.

Written informed consent for study participation obtained from the patient or parents / legal guardian, with assent as appropriate by the patient, depending on the level of understanding.

Participants consent to participate in long-term follow up and access to all relevant medical records as needed by the study team

Clinical diagnosis of vitiligo made by a dermatologist

Disqualifiers

Insufficient understanding of the study by the patient and/or parent/guardian.

Patients with vitiligo/their parents or guardians, who do not provide consent for participation.

Trial design

Treatments tested in this trial

  • Not listed

Trial groups

No trial groups listed

Sponsors and collaborators

The Royal Wolverhampton Hospitals NHS Trust

Lead sponsor

Incyte Biosciences International Sàrl

Collaborator